What are you looking for?
Geographic atrophy (GA) was associated with progressive vision loss, higher healthcare costs, and a potential increase in the risk of falls and fractures, according to a study from the American Academy of Ophthalmology IRIS Registry. Researchers evaluated 63,616 patients aged 50 years or older who had valid visual acuity (VA) measurements before and after diagnosis.... ...
This Spotlight Series article is editorially independent content. Geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD), can cause severe,...
In the Phase 3 GATHER2 trial, avacincaptad pegol (ACP) 2 mg given either monthly or every other month was associated with reduced...
Samuel Minaker, MD, MSc, of Tyler Retina Consultants, presented data at the Floretina 2025 meeting in December showing that EYP-1901 reduced the...
Geographic atrophy (GA) was associated with progressive vision loss, higher healthcare costs, and a potential increase in the risk of falls and fractures, according to a study from the American...
This Spotlight Series article is editorially independent content. Geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD), can cause severe, irreversible vision loss and disability. Although GA lesions...
In the Phase 3 GATHER2 trial, avacincaptad pegol (ACP) 2 mg given either monthly or every other month was associated with reduced geographic atrophy (GA) growth compared with sham over...
Samuel Minaker, MD, MSc, of Tyler Retina Consultants, presented data at the Floretina 2025 meeting in December showing that EYP-1901 reduced the treatment burden in patients with neovascular age-related macular...
Just over half of eyes with dry age-related macular degeneration (AMD) progressed to advanced AMD over nearly 9 years, with progression more common in older patients and those with thinner...
Extended results from the phase 3 GATHER2 study found that monthly treatment with avacincaptad pegol continued to reduce geographic atrophy (GA) lesions for up to 3.5 years. Patients who were...
Hasenin Al-Khersan, MD, of Retina Consultants of Texas, spoke with Ophthalmology 360 about an AAO 2025 study that found AI algorithms could accurately measure ophthalmic lesions from OCT scans. Hasenin...
A pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) data has identified differing safety profiles for pegcetacoplan and avacincaptad pegol, the only approved treatments for geographic atrophy, according to...